# Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

> **NCT00201123** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 89 (actual)

## Conditions studied

- Tuberculosis
- AIDS-related Complex

## Interventions

- **DRUG:** Aerosol Interferon-Gamma
- **DRUG:** Subcutaneous interferon-gamma
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00201123
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2007-01
- **Final completion:** 2007-08
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2016-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00201123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00201123, "Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00201123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*